Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Histopathologic quantification of viable tumor versus treatment effect in surgically resected recurrent glioblastoma.

Bagley SJ, Schwab RD, Nelson E, Viaene AN, Binder ZA, Lustig RA, O'Rourke DM, Brem S, Desai AS, Nasrallah MP.

J Neurooncol. 2019 Jan;141(2):421-429. doi: 10.1007/s11060-018-03050-6. Epub 2018 Nov 16.

PMID:
30446903
2.

MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.

Kim BS, Kong DS, Seol HJ, Nam DH, Lee JI.

J Neurooncol. 2017 Jul;133(3):615-622. doi: 10.1007/s11060-017-2478-9. Epub 2017 May 23.

PMID:
28536992
3.

Reoperation for Recurrent Glioblastoma and Its Association With Survival Benefit.

Tully PA, Gogos AJ, Love C, Liew D, Drummond KJ, Morokoff AP.

Neurosurgery. 2016 Nov;79(5):678-689.

PMID:
27409404
4.

Indication for repeat surgery of glioblastoma: influence of progress of disease.

Mühling M, Krage J, Hussein S, Samii M.

Front Radiat Ther Oncol. 1999;33:192-201. No abstract available.

PMID:
10549489
5.

Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.

McNamara MG, Lwin Z, Jiang H, Templeton AJ, Zadeh G, Bernstein M, Chung C, Millar BA, Laperriere N, Mason WP.

J Neurooncol. 2014 Mar;117(1):147-52. doi: 10.1007/s11060-014-1366-9. Epub 2014 Jan 28.

PMID:
24469854
6.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
7.

Pathological findings and prognostic factors in recurrent glioblastomas.

Okita Y, Narita Y, Miyakita Y, Ohno M, Fukushima S, Kayama T, Shibui S.

Brain Tumor Pathol. 2012 Oct;29(4):192-200. doi: 10.1007/s10014-012-0084-2. Epub 2012 Feb 14.

PMID:
22331317
8.

Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.

Bloch O, Han SJ, Cha S, Sun MZ, Aghi MK, McDermott MW, Berger MS, Parsa AT.

J Neurosurg. 2012 Dec;117(6):1032-8. doi: 10.3171/2012.9.JNS12504. Epub 2012 Oct 5.

PMID:
23039151
9.

Survival outcomes following repeat surgery for recurrent glioblastoma: a single-center retrospective analysis.

Perrini P, Gambacciani C, Weiss A, Pasqualetti F, Delishaj D, Paiar F, Morganti R, Vannozzi R, Lutzemberger L.

J Neurooncol. 2017 Feb;131(3):585-591. doi: 10.1007/s11060-016-2330-7. Epub 2016 Nov 14.

PMID:
27844310
10.

Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.

Metellus P, Coulibaly B, Nanni I, Fina F, Eudes N, Giorgi R, Barrie M, Chinot O, Fuentes S, Dufour H, Ouafik L, Figarella-Branger D.

Cancer. 2009 Oct 15;115(20):4783-94. doi: 10.1002/cncr.24546.

11.

Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.

Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, Magliocco A, Bredel M, Robe P, Grosu AL, Stupp R, Curran W Jr, Becker AP, Salavaggione AL, Barnholtz-Sloan JS, Aldape K, Blumenthal DT, Brown PD, Glass J, Souhami L, Lee RJ, Brachman D, Flickinger J, Won M, Chakravarti A.

JAMA Oncol. 2017 Jun 1;3(6):784-792. doi: 10.1001/jamaoncol.2016.6020.

12.

Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy.

Kreth FW, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T, Weller M, Tonn JC; German Glioma Network.

Ann Oncol. 2013 Dec;24(12):3117-23. doi: 10.1093/annonc/mdt388. Epub 2013 Oct 14.

13.

The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis.

Goldman DA, Hovinga K, Reiner AS, Esquenazi Y, Tabar V, Panageas KS.

J Neurosurg. 2018 Nov 1;129(5):1231-1239. doi: 10.3171/2017.6.JNS17393.

14.

Residual tumor volume and patient survival following reoperation for recurrent glioblastoma.

Yong RL, Wu T, Mihatov N, Shen MJ, Brown MA, Zaghloul KA, Park GE, Park JK.

J Neurosurg. 2014 Oct;121(4):802-9. doi: 10.3171/2014.6.JNS132038. Epub 2014 Jul 25.

PMID:
25061868
15.

Effects of iodine-125 brachytherapy on the proliferative capacity and histopathological features of glioblastoma recurring after initial therapy.

Siddiqi SN, Provias J, Laperriere N, Bernstein M.

Neurosurgery. 1997 May;40(5):910-7; discussion 917-8.

PMID:
9149248
16.

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.

Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, Bruey JM, Koeppen H, Liu B, Verret W, Phan SC, Shames DS.

J Clin Oncol. 2017 Jan 20;35(3):343-351. doi: 10.1200/JCO.2015.64.7685. Epub 2016 Dec 5.

PMID:
27918718
17.

Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma.

Sharma M, Bellamkonda S, Mohapatra S, Meola A, Jia X, Mohammadi A, Angelov L, Barnett GH, Vogelbaum M, Ahluwalia MS.

World Neurosurg. 2018 Aug;116:e147-e161. doi: 10.1016/j.wneu.2018.04.134. Epub 2018 Apr 27.

PMID:
29709748
18.

Impact of removed tumor volume and location on patient outcome in glioblastoma.

Awad AW, Karsy M, Sanai N, Spetzler R, Zhang Y, Xu Y, Mahan MA.

J Neurooncol. 2017 Oct;135(1):161-171. doi: 10.1007/s11060-017-2562-1. Epub 2017 Jul 6.

PMID:
28685405
19.

Usefulness of Reintervention in Recurrent Glioblastoma: An Indispensable Weapon for Increasing Survival.

Delgado-Fernandez J, Garcia-Pallero MÁ, Blasco G, Penanes JR, Gil-Simoes R, Pulido P, Sola RG.

World Neurosurg. 2017 Dec;108:610-617. doi: 10.1016/j.wneu.2017.09.062. Epub 2017 Sep 20.

PMID:
28939537
20.

Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma.

Paik W, Kim HS, Choi CG, Kim SJ.

Korean J Radiol. 2016 Jan-Feb;17(1):117-26. doi: 10.3348/kjr.2016.17.1.117. Epub 2016 Jan 6.

Supplemental Content

Support Center